^Pöldinger W (1985). "Pirlindole: results of an open clinical study in out-patients and of a double-blind study against maprotiline.".Psychiatry the State of the Art. Boston, MA.: Springer. pp. 283–289.doi:10.1007/978-1-4613-2363-1_44.ISBN978-1-4613-2363-1.
^Bruhwyler J, Liégeois JF, Géczy J (July 1997). "Pirlindole: a selective reversible inhibitor of monoamine oxidase A. A review of its preclinical properties".Pharmacological Research.36 (1):23–33.doi:10.1006/phrs.1997.0196.PMID9368911.
^Filitis LN, Fedotova OA, Akalaeva TV, Bokanov AI, Ivanov PY, Neustroeva VD, Nyrkova VG, Pershin GN, Shvedov VI (1986). "Tetrahydrocarbazole derivatives and their antitubercular activity in vitro. I. N-Substituted hexahydro-1H-pyrazino[3,2,1-j,k]carbazoles".Khimiko-Farmatsevticheskii Zhurnal (in Russian).20 (3):300–303.
^Ivanov PY, Alekseeva LM, Bokanov AI, Shvedov VI, Sheinker YN (January 1987). "New approach to the synthesis of pyrazidol".Pharmaceutical Chemistry Journal.21 (1):62–65.doi:10.1007/BF00764890.S2CID22179419..
^De Tullio P, Felikidis A, Pirotte B, Liégeois JF, Stachow M, Delarge J, Ceccato A, Hubert P, Crommen J, Géczy J (1998). "First Preparative Enantiomer Resolution of Pirlindole, a Potent Antidepressant Drug".Helvetica Chimica Acta.81 (3–4):539–547.Bibcode:1998HChAc..81..539D.doi:10.1002/hlca.19980810307.ISSN0018-019X..
^,FR 2132514 (1972 to Inst Im Sergo); CA, 78, 124628r
^Massimo Ferrari, et al.EP 1044976 (2002 to Erregierre SpA).